July 13, 2016 / 12:47 PM / a year ago

BRIEF-Nuvo pharmaceuticals to study Pennsaid 2 pct

1 Min Read

July 13 (Reuters) - Nuvo Pharmaceuticals Inc

* Nuvo Pharmaceuticals Inc. announces Pennsaid 2 percent phase 3 trial to support regulatory approvals in the E.U., Canada and Australia

* Will conduct a new placebo-controlled, multi-centre phase 3 trial in Germany to study Pennsaid 2 percent for treatment of acute ankle sprains Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below